Ku antigen is required to relieve G2 arrest caused by inhibition of DNA topoisomerase II activity by the bisdioxopiperazine ICRF-193

被引:7
|
作者
Muñoz, P [1 ]
Baus, F [1 ]
Piette, J [1 ]
机构
[1] Inst Genet Mol Montpellier, CNRS, UMR 5535, F-34293 Montpellier 5, France
关键词
cell cycle; DNA topoisomerase II; Ku antigen; DNA replication;
D O I
10.1038/sj.onc.1204262
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ku antigen is necessary for DNA double-strand break (DSB) repair through its ability to bind DNA ends with high affinity and to recruit the catalytic subunit of DNA-PK to the DSBs, Ku-deficient cells are hypersensitive to agents causing DSBs in DNA but also to the DNA topoisomerase II (topo II) inhibitor ICRF-193, which does not induce DSBs, This suggests a new role of Ku antigen, that is independent of DSB repair by DNA-PK. Here we characterize the basis for the hypersensitivity of Ku-deficient cells to ICRF-193, Chromosome condensation and segregation, which are dependent on topo II, but also the catalytic activity of topo II in Late S-G2 were inhibited to a comparable extent when ICRF-193 was applied to Ku-deficient cells or wild-type cells. However, mutant cells arrested in G2 by ICRF-193 treatment were unable to progress into M phase upon drug removal, although drug-trapped topo II complexes were removed from DNA and the two isoforms of topo II recovered their catalytic activity as in wild-type cells, The reversibility of G2 arrest was recovered by complementation of mutant cells with a human Ku86 cDNA, Notably, chromosome condensation was abnormal in Ku-deficient cells after suppression of the G2 arrest by caffeine, even in the absence of ICRF-193, These results reflect the involvement of Ku-antigen in the cellular response to topo II inhibition, more particularly in relieving G2 arrest caused by topo II inhibition in late S/G2 and the subsequent recovery of chromosome condensation.
引用
收藏
页码:1990 / 1999
页数:10
相关论文
共 24 条
  • [1] Ku antigen is required to relieve G2 arrest caused by inhibition of DNA topoisomerase II activity by the bisdioxopiperazine ICRF-193
    Purificación Muñoz
    Fabienne Baus
    Jacques Piette
    Oncogene, 2001, 20 : 1990 - 1999
  • [2] DNA TOPOISOMERASE-II IS THE MOLECULAR TARGET OF BISDIOXOPIPERAZINE DERIVATIVES ICRF-159 AND ICRF-193 IN SACCHAROMYCES-CEREVISIAE
    ISHIDA, R
    HAMATAKE, M
    WASSERMAN, RA
    NITISS, JL
    WANG, JC
    ANDOH, T
    CANCER RESEARCH, 1995, 55 (11) : 2299 - 2303
  • [3] Hypersensitivity of Ku-deficient cells toward the DNA topoisomerase II inhibitor ICRF-193 suggests a novel role for Ku antigen during the G2 and m phases of the cell cycle
    Muñoz, P
    Zdzienicka, MZ
    Blanchard, JM
    Piette, J
    MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (10) : 5797 - 5808
  • [4] Chk1 is required for G2/M checkpoint response induced by the catalytic topoisomerase II inhibitor ICRF-193
    Robinson, Helen M. R.
    Bratlie-Thoresen, Sigrid
    Brown, Robert
    Gillespie, David A. F.
    CELL CYCLE, 2007, 6 (10) : 1265 - 1267
  • [5] DNA topoisomerase II as the cellular target of a novel antitumor agent ICRF-193, a bisdioxopiperazine derivative, in Xenopus egg extract
    Sato, M
    Ishida, R
    Ohsumi, K
    Narita, T
    Andoh, T
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 235 (03) : 571 - 575
  • [6] The SUMO pathway is required for selective degradation of DNA topoisomerase IIβ induced by a catalytic inhibitor ICRF-193
    Isik, S
    Sano, K
    Tsutsui, K
    Seki, M
    Enomoto, T
    Saitoh, H
    Tsutsui, K
    FEBS LETTERS, 2003, 546 (2-3): : 374 - 378
  • [7] Selective inhibition of topoisomerase II by ICRF-193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells
    Beere, HM
    Chresta, CM
    Hickman, JA
    MOLECULAR PHARMACOLOGY, 1996, 49 (05) : 842 - 851
  • [8] INHIBITION OF DNA TOPOISOMERASE-II BY ICRF-193 INDUCES POLYPLOIDIZATION BY UNCOUPLING CHROMOSOME DYNAMICS FROM OTHER CELL-CYCLE EVENTS
    ISHIDA, R
    SATO, M
    NARITA, T
    UTSUMI, KR
    NISHIMOTO, T
    MORITA, T
    NAGATA, H
    ANDOH, T
    JOURNAL OF CELL BIOLOGY, 1994, 126 (06): : 1341 - 1351
  • [9] Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions
    Jirkovska, Anna
    Karabanovich, Galina
    Kubes, Jan
    Skalicka, Veronika
    Melnikova, Iuliia
    Korabecny, Jan
    Kucera, Tomas
    Jirkovsky, Eduard
    Novakova, Lucie
    Piskackova, Hana Bavlovic
    Skoda, Josef
    Sterba, Martin
    Austin, Caroline A.
    Simunek, Tomas
    Roh, Jaroslav
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (07) : 3997 - 4019
  • [10] ICRF-193, a catalytic inhibitor of DNA topoisomerase II, delays the cell cycle progression from metaphase, but not from anaphase to the G1 phase in mammalian cells
    Iwai, M
    Hara, A
    Andoh, T
    Ishida, R
    FEBS LETTERS, 1997, 406 (03) : 267 - 270